The potential for PARPi treatments in men with mCRPC with germline and somatic mutations of BRCA1 and BRCA2 are well recognized, further studies are required to fully appreciate genomic results in PCa in non BRCA HRD tumors. This evidence concerns the gene BRCA2 and posterior cortical atrophy.